Houston, TX – August 15th 2025 – OmniScience, the AI company behind Vivo, the first agentic AI control tower for clinical trials, announced today that it has been selected as one of just six companies to compete in the highly selective DPHARM Idol Disrupt competition.

DPHARM Idol participants are chosen by the DPHARM Advisory Board for their ability to deliver innovation that is not only groundbreaking but truly disruptive reshaping how clinical trials are conducted. The competition, a centerpiece of the annual DPHARM: Disruptive Innovations to Advance Clinical Trials conference, challenges participants to present transformative solutions to a panel of industry leaders and a live audience.

“We built Vivo to redefine what’s possible in clinical trial operations—unifying fragmented data, automating oversight, and delivering real-time, explainable insights that improve trial speed, cost, decisions, and outcomes,” said Angela Holmes, CEO of OmniScience. “Being selected for DPHARM Idol is an incredible opportunity to share how agentic AI can transform the way trials are run, and to stand alongside other innovators committed to pushing the industry forward.”

Vivo empowers trial teams to reduce manual work by up to 70%, cut trial costs by 20%, and improve probability of success all while maintaining regulatory-grade auditability. Competing at DPHARM Idol reflects OmniScience’s continued leadership in driving meaningful, scalable change across the life sciences industry.